LLY

913.22

-1.54%↓

JNJ

237.16

-0.76%↓

ABBV

207.78

-6.36%↓

NVS

150.25

-3.03%↓

AZN

188.98

-1.05%↓

LLY

913.22

-1.54%↓

JNJ

237.16

-0.76%↓

ABBV

207.78

-6.36%↓

NVS

150.25

-3.03%↓

AZN

188.98

-1.05%↓

LLY

913.22

-1.54%↓

JNJ

237.16

-0.76%↓

ABBV

207.78

-6.36%↓

NVS

150.25

-3.03%↓

AZN

188.98

-1.05%↓

LLY

913.22

-1.54%↓

JNJ

237.16

-0.76%↓

ABBV

207.78

-6.36%↓

NVS

150.25

-3.03%↓

AZN

188.98

-1.05%↓

LLY

913.22

-1.54%↓

JNJ

237.16

-0.76%↓

ABBV

207.78

-6.36%↓

NVS

150.25

-3.03%↓

AZN

188.98

-1.05%↓

Search

Guardant Health Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

87.54 -1.2

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

86.68

Max

89.67

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-36M

-128M

Pardavimai

16M

281M

Pelnas, tenkantis vienai akcijai

-0.5

Pelno marža

-45.684

Darbuotojai

2,490

EBITDA

-37M

-119M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+49.54% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-04-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-2.2B

11B

Ankstesnė atidarymo kaina

88.74

Ankstesnė uždarymo kaina

87.54

Naujienos nuotaikos

By Acuity

50%

50%

156 / 351 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Guardant Health Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-17 22:42; UTC

Uždarbis

Prudential PLC 2025 Adjusted Operating Profit Rises

2026-03-17 21:40; UTC

Uždarbis

Alimentation Couche-Tard Records Higher Profit, Revenue in 3Q

2026-03-17 23:56; UTC

Rinkos pokalbiai

BHP's Next CEO Likely to Build On Existing Strategic Direction -- Market Talk

2026-03-17 23:46; UTC

Rinkos pokalbiai

Nikkei May Rise After Recent Selloffs -- Market Talk

2026-03-17 23:42; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-17 23:42; UTC

Rinkos pokalbiai

RBA's Return to Policy Tightening Will Work -- Market Talk

2026-03-17 23:38; UTC

Rinkos pokalbiai

Gold Edges Lower on Possible Position Adjustments Before FOMC Decision -- Market Talk

2026-03-17 23:24; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2026-03-17 23:24; UTC

Rinkos pokalbiai

New Woodside CEO Seen as Low-Risk Appointment -- Market Talk

2026-03-17 22:22; UTC

Rinkos pokalbiai

BHP Hands Reins to Growth-Focused Executive -- Market Talk

2026-03-17 22:20; UTC

Uždarbis

Prudential PLC 2025 New Business Profit $2.78B Vs. $2.46B >2378.HK

2026-03-17 22:20; UTC

Uždarbis

Prudential PLC 2025 Adj Operating Profit $3.31B Vs. $3.13B >2378.HK

2026-03-17 22:07; UTC

Uždarbis

Nvidia Says It Is Restarting Production of AI Chips for Sale in China -- WSJ

2026-03-17 22:05; UTC

Uždarbis

ZTO Express (Cayman): Frank Zhen Wei to Resign From Board

2026-03-17 22:04; UTC

Uždarbis

ZTO Express (Cayman): Board Approves Repurchase of Up to $1.5B of Shares Over Next 24 Months >ZTO

2026-03-17 22:03; UTC

Uždarbis

ZTO Express (Cayman) Raises Semiannual Dividend to 39c Vs. 30c >ZTO

2026-03-17 22:01; UTC

Uždarbis

ZTO Express (Cayman) 4Q Adj EPS 47c >ZTO

2026-03-17 22:01; UTC

Uždarbis

ZTO Express (Cayman) 4Q Rev $2.08B >ZTO

2026-03-17 22:01; UTC

Uždarbis

ZTO Express (Cayman) 4Q EPS 47c >ZTO

2026-03-17 21:26; UTC

Uždarbis

Oklo Stock Wavers After Earnings, but the Nuclear Start-Up Has Good News -- Barrons.com

2026-03-17 21:09; UTC

Uždarbis

Couche-Tard: 12 Company-Operated Stores Acquired During 3Q

2026-03-17 21:08; UTC

Uždarbis

Couche-Tard 3Q Consolidated Same-Store Merchandise Revenue Up 2% >ATD.T

2026-03-17 21:08; UTC

Uždarbis

Couche-Tard 3Q Adj EPS 81c >ATD.T

2026-03-17 21:07; UTC

Uždarbis

Couche-Tard 3Q EPS 82c >ATD.T

2026-03-17 21:06; UTC

Uždarbis

Couche-Tard 3Q Rev $21.8B >ATD.T

2026-03-17 21:05; UTC

Uždarbis

Couche-Tard 3Q Adj EPS 81c >ATD.T

2026-03-17 21:05; UTC

Uždarbis

Couche-Tard 3Q Rev $21.8B >ATD.T

2026-03-17 21:05; UTC

Uždarbis

Couche-Tard 3Q EPS 82c >ATD.T

2026-03-17 21:05; UTC

Uždarbis

Couche-Tard 3Q Net $757.2M >ATD.T

2026-03-17 20:50; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Energy & Utilities Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Guardant Health Inc Prognozė

Kainos tikslas

By TipRanks

49.54% į viršų

12 mėnesių prognozė

Vidutinis 132.72 USD  49.54%

Aukščiausias 175 USD

Žemiausias 110 USD

Remiantis 20 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Guardant Health Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

20 ratings

19

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

38.86 / 47.41Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

156 / 351 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat